Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death.
Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C. Cabibbo G, et al. Among authors: celsa c. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-2582. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576248
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. D'Alessio A, et al. Among authors: celsa c. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. Lancet Oncol. 2024. PMID: 39437804 Free article.
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.
Stefanini B, Manfredi GF, D'Alessio A, Fulgenzi CAM, Awosika N, Celsa C, Pirisi M, Rigamonti C, Burlone M, Vincenzi F, Minisini R, Gennari A, Yip V, Slater S, El-Shakankery K, Jain A, Tovoli F, Piscaglia F, Spalding D, Pai M, Pinato DJ. Stefanini B, et al. Among authors: celsa c. Expert Rev Gastroenterol Hepatol. 2024 Oct;18(10):647-660. doi: 10.1080/17474124.2024.2419519. Epub 2024 Oct 22. Expert Rev Gastroenterol Hepatol. 2024. PMID: 39435480 Review.
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Rimini M, Montes M, Amadeo E, Vitiello F, Kudo M, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Salani F, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Camera S, Rossari F, Foti S, Kumada T, Hiraoka A, Iwamoto H, Rizzato MD, Himmelsbach V, Masi G, Corradi M, Celsa C, Fabio C, Frassineti GL, Cascinu S, Casadei-Gardini A, Presa J. Rimini M, et al. Among authors: celsa c. Sci Rep. 2024 Aug 30;14(1):20200. doi: 10.1038/s41598-024-70928-z. Sci Rep. 2024. PMID: 39215078 Free PMC article.
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies.
Pennisi G, Infantino G, Celsa C, Di Maria G, Enea M, Vaccaro M, Cannella R, Ciccioli C, La Mantia C, Mantovani A, Mercurio F, Tilg H, Targher G, Di Marco V, Cammà C, Petta S. Pennisi G, et al. Among authors: celsa c. Liver Int. 2024 Nov;44(11):2939-2949. doi: 10.1111/liv.16075. Epub 2024 Aug 19. Liver Int. 2024. PMID: 39157862
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C, Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon HJ, Cammà C, Pinato DJ. Celsa C, et al. Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026. Online ahead of print. Hepatology. 2024. PMID: 39028886
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
Fulgenzi CAM, Scheiner B, D'Alessio A, Mehan A, Manfredi GF, Celsa C, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Pirisi M, Park JW, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini EG, Cortellini A, Pinato DJ. Fulgenzi CAM, et al. Among authors: celsa c. JAMA Oncol. 2024 Sep 1;10(9):1253-1258. doi: 10.1001/jamaoncol.2024.2166. JAMA Oncol. 2024. PMID: 39023864
80 results